Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR : Pathophysiology and Management
Joint Authors
Piperdi, Bilal
Abdullah, Shaad E.
Haigentz, Missak
Source
Chemotherapy Research and Practice
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-09-11
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Epidermal growth factor receptor (EGFR) inhibition has now been well established as an effective treatment for various cancers.
The EGFR belongs to the ErbB family of tyrosine kinase receptors which regulate tumor cell differentiation, survival and proliferation.
Activation of EGFR drives tumorigenesis in lung, head and neck, colorectal and pancreatic cancers.
Irrespective of the type of cancer being treated and the mechanism by which tumor EGFR drives tumorigenesis, the major side effect of EGFR inhibition is a papulopustular (also described as maculopapular or acneiform) rash which occurs in about two thirds of treated patients.
Interestingly, this rash has been commonly correlated with better clinical outcomes (objective tumor response and patient survival).
The pathophysiology of dermatological toxicity from EGFR inhibitors is an important area of clinical research, and the proper management of the rash is essential to increase the therapeutic index from this class of drugs.
In this paper, we review the dermatologic toxicities associated with EGFR inhibitors with an emphasis on its pathophysiology and clinical management.
American Psychological Association (APA)
Abdullah, Shaad E.& Haigentz, Missak& Piperdi, Bilal. 2012. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR : Pathophysiology and Management. Chemotherapy Research and Practice،Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-464990
Modern Language Association (MLA)
Abdullah, Shaad E.…[et al.]. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR : Pathophysiology and Management. Chemotherapy Research and Practice No. 2012 (2012), pp.1-10.
https://search.emarefa.net/detail/BIM-464990
American Medical Association (AMA)
Abdullah, Shaad E.& Haigentz, Missak& Piperdi, Bilal. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR : Pathophysiology and Management. Chemotherapy Research and Practice. 2012. Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-464990
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-464990